Basaglar (insulin glargine) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to: improve blood sugar levels in adults ...

After years of manufacturing woes torpedoed their chances to challenge Sanofi's blockbuster insulin injection Lantus, Mylan and Biocon recently received the FDA's go-ahead to launch their knockoff.

The follow-on or copycat insulin glargine product Basaglar (Lilly) is similar to brand-name Lantus (Sanofi) in terms of efficacy and safety for the treatment of type 2 diabetes, but Basaglar cost less ...

Tresiba (insulin degludec) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to treat type 1 and type 2 diabetes in ...

Sanofi has inaugurated a new assembling and packaging line to produce its flagship pre-filled insulin injection pen Lantus SoloSTAR at its Beijing plant located at the Beijing Economic-Technological ...

Here's some welcome news for diabetics dealing with the high price of insulin: The Food and Drug Administration has approved Mylan (MYL +0.00%) and Biocon's Semglee, which is essentially identical to ...